Positive Phase III data for upadacitinib monotherapy in the treatment of adults and adolescents with moderate to severe atopic dermatitis

An EASI 75 response at week 16 was achieved in 70% (15mg upadacitinib) and 80% (30mg) vs. 16% with placebo (p<0.001). A validated Investigator's Global Assessment for Atopic Dermatitis of clear or almost clear was achieved by 48%, 62% and 8%, respectively (p<0.001).


Biospace Inc.